Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27005634 | 0.81 | TOP2A (0.32) | — | |
| SCHEMBL6696769 | 0.80 | DAO (0.31) | — | |
| SCHEMBL5957191 | 0.77 | TUBB4A (0.32) | — | |
| SCHEMBL99567 | 0.74 | ACHE (0.34) | BCHEACHEPTGS2 | |
| SCHEMBL27870429 | 0.69 | — | — | |
| SCHEMBL9967707 | 0.69 | — | — | |
| SCHEMBL101641 | 0.69 | FDPS (0.35) | BCHEACHEPTGS2 | |
| SCHEMBL101642 | 0.69 | FDPS (0.35) | BCHEACHEPTGS2 | |
| SCHEMBL2475342 | 0.68 | WRN (0.33) | BCHEACHEPTGS2 | |
| SCHEMBL10531121 | 0.67 | GSK3B (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113620940-B | Preparation of near-infrared absorption amphiphilic diaryl alkene photochromic molecules and application of amphiphilic diaryl alkene photochromic molecules in reversible photothermal and photoacoustic applications | 北京化工大学 | 2023-12-15 | — | — | CN | claimed |
| CN-113620940-A | Preparation of near-infrared absorbing amphiphilic diarylethene photochromic molecules and application of reversible photo-thermal and photo-acoustic molecules | 北京化工大学 | 2021-11-09 | — | — | CN | claimed |
| CN-113620940-B | Preparation of near-infrared absorption amphiphilic diaryl alkene photochromic molecules and application of amphiphilic diaryl alkene photochromic molecules in reversible photothermal and photoacoustic applications | 北京化工大学 | 2023-12-15 | — | — | CN | disclosed |
| EP-3838903-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2023-11-22 | — | — | EP | disclosed |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2022-12-15 | — | — | US | disclosed |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-05-17 | — | — | US | disclosed |
| CN-113620940-A | Preparation of near-infrared absorbing amphiphilic diarylethene photochromic molecules and application of reversible photo-thermal and photo-acoustic molecules | 北京化工大学 | 2021-11-09 | — | — | CN | disclosed |
| EP-3838903-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2021-06-23 | — | — | EP | disclosed |
| EP-3466953-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2021-02-03 | — | — | EP | disclosed |
| US-20200338077-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2020-10-29 | — | — | US | disclosed |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | INCYTE CORPORATION | 2007-06-14 | — | — | US | disclosed |
| US-20060293343-A1 | Pyrimidine derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-12-28 | — | — | US | disclosed |
| US-20040229910-A1 | Therapeutic compounds | N.V. ORGANON (NL) | 2004-11-18 | — | — | US | disclosed |
| US-20020037885-A1 | Therapeutic compounds | DIJCKS FREDERICUS ANTONIUS (NL) | 2002-03-28 | — | — | US | disclosed |
| US-6313139-B1 | ADMINISTERING BENZYLAMINE DERIVATIVE FOR THERAPY OF PSYCHIATRIC DISORDER IN MAMMALS | AKZO NOBEL N. V. (NL) | 2001-11-06 | — | — | US | disclosed |
| CN-1275909-A | In-modulators | AKZO NOBEL NV (NL) | 2000-12-06 | — | — | CN | disclosed |
| EP-1035843-A2 | I h?-MODULATORS | Akzo Nobel N.V. (NL) | 2000-09-20 | — | — | EP | disclosed |
| US-6080773-A | USEFUL FOR TREATMENT OF DEPRESSION, ANXIETY OR PSYCHOSIS | AKZO NOBEL, N.V. (NL) | 2000-06-27 | — | — | US | disclosed |
| WO-1999018941-A2 | Ih-MODULATORS | AKZO NOBEL N.V. (NL) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200338077-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | BCHE 4718/4885ACHE 4875/4885PTGS2 915/4885 |
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | BCHE 4718/4885ACHE 4875/4885PTGS2 915/4885 |
| US-20060293343-A1 | Pyrimidine derivatives | PDE4A, PDE4B, PDE5A | BCHE 1749/4885ACHE 680/4885PTGS2 999/4885 |
| US-20040229910-A1 | Therapeutic compounds | BDNF, PNMT, SLC18A2 | BCHE 277/4885ACHE 484/4885PTGS2 1070/4885 |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | JAK1, JAK3, MAP3K4 | BCHE 4723/4885ACHE 4867/4885PTGS2 1385/4885 |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | BCHE 4718/4885ACHE 4875/4885PTGS2 915/4885 |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | BCHE 4718/4885ACHE 4875/4885PTGS2 915/4885 |
| US-20020037885-A1 | Therapeutic compounds | BDNF, PNMT, SLC18A2 | BCHE 277/4885ACHE 484/4885PTGS2 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.